EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

α-Tocotrienol and Redox-Silent Analogs of Vitamin E Enhances Bortezomib Sensitivity in Solid Cancer Cells through Modulation of NFE2L1

Kyota Ishii, Mayuko Hido, Misaki Sakamura, Nantiga Virgona, Tomohiro Yano iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24119382 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Kyota Ishii und 4 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Molecular Bromacology, Graduate School of Sports Health, Toyo University, Akabane City 115-8650, Japan. Hauptthemen laut MEDLINE: Antineoplastic Agents, Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Inoue Enryou Memorial Foundation of Toyo University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Proteasome inhibitors (PIs) have emerged as an attractive novel cancer therapy. However, most solid cancers are seemingly resistant to PIs. The activation of transcription factor Nuclear factor erythroid 2 related factor-1 (NFE2L1) has been characterized as a potential resistance response to protect and restore proteasome activity in cancer cells. In this study, we demonstrated that α-Tocotrienol (T3) and redox-silent analogs of vitamin E (TOS, T3E) enhanced the sensitivity of bortezomib (BTZ), a proteasome inhibitor, in solid cancers through modulation of NFE2L1. In BTZ treatment, all of T3, TOS, and T3E inhibited an increase in the protein levels of NFE2L1, the expression levels of proteasome-related proteins, as well as the recovery of proteasome activity. Moreover, the combination of one of T3, TOS, or T3E and BTZ induced a significant decrease in cell viability in solid cancer cell lines. These findings suggested that the inactivation of NFE2L1 by T3, TOS, and T3E is essential to potentiate the cytotoxic effect of the proteasome inhibitor, BTZ, in solid cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsNeoplasmsBortezomibProteasome InhibitorsVitamin EProteasome Endopeptidase ComplexCell Line, TumorOxidation-ReductionDrug Resistance, NeoplasmTocotrienols

Stichwörter der Autor:innen

NFE2L1bortezomibproteasome inhibitorvitamin E

Substanzen

BortezomibProteasome InhibitorsVitamin EProteasome Endopeptidase ComplexAntineoplastic Agentstocotrienol, alphaTocotrienols

Autor:innen und Institutionen

  • Laboratory of Molecular Bromacology, Graduate School of Sports Health, Toyo University, Akabane City 115-8650, Japan.
  • Department of Food and Nutritional Sciences, Faculty of Food and Nutritional Sciences, Toyo University, Itakura 374-0193, Japan.
  • Research Institute of Life Innovation, Toyo University, Akabane City 115-8650, Japan.

ORCID-Profile: Tomohiro Yano

Förderung

  • Inoue Enryou Memorial Foundation of Toyo University

Zitieren

APA

Ishii, K., Hido, M., Sakamura, M., Virgona, N., & Yano, T. (2023). α-Tocotrienol and Redox-Silent Analogs of Vitamin E Enhances Bortezomib Sensitivity in Solid Cancer Cells through Modulation of NFE2L1. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24119382

Vancouver

Ishii K, Hido M, Sakamura M, Virgona N, Yano T. α-Tocotrienol and Redox-Silent Analogs of Vitamin E Enhances Bortezomib Sensitivity in Solid Cancer Cells through Modulation of NFE2L1. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24119382

BibTeX
@article{Ishii2023,
  author = {Ishii, Kyota and Hido, Mayuko and Sakamura, Misaki and Virgona, Nantiga and Yano, Tomohiro},
  title = {α-Tocotrienol and Redox-Silent Analogs of Vitamin E Enhances Bortezomib Sensitivity in Solid Cancer Cells through Modulation of NFE2L1},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24119382}
}
Kostenlos starten →